---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000168"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:28:01.799407+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharma appoints CEO, CSO, CBO with $225k salary and 35% bonus

## Summary
- Frederick E. Pierce appointed CEO, Dr. Barbara Hibner as CSO, Peter Marschel as CBO effective upon merger closing.
- Each executive receives annual base salary of $225,000 and target annual bonus of 35% of base salary.
- Severance includes $225,000 lump sum plus 9 months COBRA reimbursement if terminated without cause or for good reason.
- Employment agreements incorporate at-will status, restrictive covenants, and eligibility for standard benefits.

## SEC filing metadata
- accession: 0001615219-25-000168
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000168/0001615219-25-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000168/flks-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000168
- JSON: https://secwatch.observer/filing/0001615219-25-000168.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.